<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Neuromuscular Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Neuromuscular Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Нервно-мышечные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-8721</issn><issn publication-format="electronic">2413-0443</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">672</article-id><article-id pub-id-type="doi">10.17650/2222-8721-2025-15-4-24-29</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Myasthenia gravis in the Republic of Bashkortostan: analysis of clinical and functional features</article-title><trans-title-group xml:lang="ru"><trans-title>Миастения в Республике Башкортостан: анализ клинико-функциональных особенностей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6782-6064</contrib-id><name-alternatives><name xml:lang="en"><surname>Berg</surname><given-names>Adel V.</given-names></name><name xml:lang="ru"><surname>Берг</surname><given-names>Адель Вадимовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>adel.basharova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1001-2024</contrib-id><name-alternatives><name xml:lang="en"><surname>Kutlubaev</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Кутлубаев</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>adel.basharova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Bashkir State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-03-06" publication-format="electronic"><day>06</day><month>03</month><year>2026</year></pub-date><volume>15</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>24</fpage><lpage>29</lpage><history><date date-type="received" iso-8601-date="2025-12-22"><day>22</day><month>12</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Berg A.V., Kutlubaev M.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Берг А.В., Кутлубаев М.А.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Berg A.V., Kutlubaev M.A.</copyright-holder><copyright-holder xml:lang="ru">Берг А.В., Кутлубаев М.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://nmb.abvpress.ru/jour/article/view/672">https://nmb.abvpress.ru/jour/article/view/672</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Myasthenia gravis (MG) is a chronic autoimmune disease that significantly affects patients’ quality of life. Studying the regional characteristics of MG is important for optimizing medical care.</p> <p><bold>Aim.</bold> To study the socio-demographic and clinical-functional characteristics of patients with MG in the Republic of Bashkortostan.</p> <p><bold>Materials and methods. </bold>A cross-sectional study was conducted based on data from the Republican Medical Information and Analytical System as of 01.01.2024. Data from 249 patients diagnosed with MG (G70.0) were analyzed.</p> <p><bold>Results.</bold> Data from 249 patients with MG were analyzed. Women (70.3 %) and individuals over 50 years of age (69 %) predominated among them. The mean age of disease onset was 43.1 years. The generalized form of MG was diagnosed in 86.7 % of patients and was significantly more common in women. Approximately half of the patients had a disability. During the year, 63.4 % of patients visited a neurologist on an outpatient basis, and 52.2 % received inpatient treatment. All patients received pyridostigmine bromide, in combination with glucocorticoids – 66.6 %, and with cytostatics – 2.8 %. Thymectomy was performed in 12.4 % of patients. High comorbidity was noted: on average, there were 3 comorbid conditions per patient.</p> <p><bold>Conclusion.</bold> The study results demonstrate the high medical and social significance of MG in the Republic of Bashkortostan. Enhancement of outpatient medical care for patients with myasthenia gravis in the Republic of Bashkortostan and implementation of more personalized treatment approaches are required.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Миастения гравис (МГ) является хроническим аутоиммунным заболеванием, существенно влияющим на качество жизни пациентов. Изучение региональных особенностей МГ важно для оптимизации медицинской помощи.</p> <p><bold>Цель исследования</bold> – изучить социально-демографические и клинико-функциональные особенности пациентов с МГ в Республике Башкортостан.</p> <p><bold>Материалы и методы.</bold> Проведено одномоментное исследование на основе данных Республиканской медицинской информационно-аналитической системы по состоянию на 01.01.2024. Проанализированы данные 249 пациентов с диагнозом МГ (G70.0).</p> <p><bold>Результаты.</bold> Проанализированы данные 249 пациентов с МГ. Среди них преобладали женщины (70,3 %) и лица старше 50 лет (69 %). Средний возраст дебюта заболевания – 43,1 года. Генерализованная форма МГ диагностирована у 86,7 % пациентов, при этом она достоверно чаще встречалась у женщин. Около половины пациентов имели инвалидность. В течение года к неврологу амбулаторно обращались 63,4 % пациентов, а стационарное лечение получили 52,2 %. Все пациенты получали антихолинэстеразные препараты, в комбинации с глюкокортикостероидами – 66,6 % пациентов, в комбинации с цитостатиками – 2,8 %. Тимэктомия была выполнена 12,4 % пациентов. Отмечена высокая коморбидность: в среднем на 1 пациента с МГ приходилось 3 сопутствующих заболевания.</p> <p><bold>Выводы.</bold> Результаты исследования демонстрируют высокую медико-социальную значимость МГ в Республике Башкортостан. Необходимо усиление амбулаторной медицинской помощи пациентам с МГ в Республике Башкортостан, а также внедрение более персонализированных подходов к лечению.</p></trans-abstract><kwd-group xml:lang="en"><kwd>myasthenia gravis</kwd><kwd>epidemiology</kwd><kwd>Republic of Bashkortostan</kwd><kwd>comorbidity</kwd><kwd>immunosuppressive therapy</kwd><kwd>disability</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>миастения гравис</kwd><kwd>эпидемиология</kwd><kwd>Республика Башкортостан</kwd><kwd>коморбидность</kwd><kwd>иммуносупрессивная терапия</kwd><kwd>инвалидность</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This work was supported by the Bashkir State Medical University Strategic Academic Leadership Program (“PRIORITY-2030”)</funding-statement><funding-statement xml:lang="ru">Работа выполнена за счет средств Программы стратегического академического лидерства Башкирского государственного медицинского университета («ПРИОРИТЕТ-2030»)</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Juel V.C. Autoimmune myasthenia gravis. Continuum (Minneap Minn) 2025;31(5):1270–302. DOI: 10.1212/cont.0000000000001612</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Alekseeva T.M., Kryuchkova V.V., Stuchevskaya T.R., Khalmurzina A.N. Epidemiologic studies of myasthenia gravis: literature review. Nervno-myshechnye bolezni = Neuromuscular Diseases 2018;8 (3):12–8. (In Russ.). DOI: 10.17650/2222-8721-2018-8-3-12-18</mixed-citation><mixed-citation xml:lang="ru">Алексеева Т.М., Крючкова В.В., Стучевская Т.Р., Халмурзина А.Н. Эпидемиологические исследования миастении: обзор литературы. Нервно-мышечные болезни 2018;8(3):12–8. DOI: 10.17650/2222-8721-2018-8-3-12-18</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Gilhus N.E., Breiner A. Epidemiology of myasthenia gravis. Int Rev Neurobiol 2025;182:161–96. DOI: 10.1016/bs.irn.2025.04.028</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Berg A.V., Kutlubaev M.A. Analysis of the incidence of myasthenia gravis in the Republic of Bashkortostan during 2013–2022. Rossiyskiy nevrologicheskiy zhurnal = Russian Neurological Journal 2025;30(4): 18–21. (In Russ.) . DOI: 10.30629/2658-7947-2025-30-4-18-21</mixed-citation><mixed-citation xml:lang="ru">Берг А.В., Кутлубаев М.А. Анализ заболеваемости миастенией в Республике Башкортостан за 2013–2022 гг. Российский неврологический журнал 2025;30(4):18–21. DOI: 10.30629/2658-7947-2025-30-4-18-21</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Narayanaswami P., Verity R., Vissing J. Novel treatments for myasthenia gravis. Int Rev Neurobiol 2025;183:133–60. DOI: 10.1016/bs.irn.2025.08.001</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Okuno T., Koizumi N., Yasumizu Y. Pathogenesis of thymoma-associated myasthenia gravis: a narrative review. Mediastinum 2025;9:26. DOI: 10.21037/med-25-28</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>O’Connor L., Barnett-Tapia C. Myasthenia gravis in women. Int Rev Neurobiol 2025;183:45–58. DOI: 10.1016/bs.irn.2025.04.020</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Beeching F., Lecchi A., Riccitelli G.C. Female gender and quality of life outcomes in myasthenia gravis: a systematic review and meta-analysis. Ther Adv Neurol Disord 2025;18:17562864251344742. DOI: 10.1177/17562864251344742</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zhou R., Li T., Tian K., Huang L. Exploration the effect of air pollution on the incidence of myasthenia gravis: an empirical study from Chengdu. Atmospheric Pollution Research 2025;16(5):102477. DOI: 10.1016/j.apr.2025.102477</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Yoshikawa H., Adachi Y., Nakamura Y. et al. Comparative study of Japanese nationwide epidemiological studies of myasthenia gravis using datasets of 2006 and 2018. PLoS One 2025;20(10):e0334041. DOI: 10.1371/journal.pone.0334041</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Shao T., Lu J., Kang H. et al. Diabetes mellitus in patients with myasthenia gravis: a systematic review and meta-analysis. Endocrine 2025;88(1):24–35. DOI: 10.1007/s12020-024-04143-1</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Croitoru C.G., Pavel-Tanasa M., Cuciureanu D.I. et al. Autoimmune and non-autoimmune comorbidities in myasthenic patients of East-European descent: a case-control study. J Clin Med 2024;13(8):2273. DOI: 10.3390/jcm13082273</mixed-citation></ref></ref-list></back></article>
